| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Oxonol VI targets the plasma membrane, where it distributes according to the membrane potential (electrophoretic distribution). Its fluorescence decreases upon membrane hyperpolarization and increases upon depolarization.
|
|---|---|
| ln Vitro |
In lipid vesicles, Oxonol VI serves as an optical indicator and detects changes in membrane potential associated with Na+/K+-ATPase activity. Quantitative membrane potential measurements are easily calibrated due to its fluorescence response to potential changes.
|
| ln Vivo |
No in vivo activity data are documented, as Oxonol VI is primarily used for in vitro membrane potential measurements in reconstituted vesicles or isolated cells, not for systemic in vivo administration.
|
| Enzyme Assay |
Oxonol VI is added to purified lipid vesicles reconstituted with Na+/K+-ATPase at 1-10 uM. Membrane potential is altered by varying K+ gradients or adding ATP. Fluorescence is monitored at Ex/Em 523/630 nm. Potential is calibrated using valinomycin-induced K+ diffusion potentials.
|
| Cell Assay |
Cells are loaded with 1-5 uM Oxonol VI in physiological buffer for 15-30 min at 37degC. Fluorescence intensity is measured at Ex/Em 523/630 nm. Membrane potential changes are induced by ion channel modulators or by altering extracellular ion concentrations.
|
| Animal Protocol |
Oxonol VI is not for in vivo animal administration. For ex vivo studies, isolated tissues or primary cells are prepared and incubated with 2-5 uM dye for 20-30 min, then membrane potential changes are recorded fluorometrically upon pharmacological stimulation.
|
| ADME/Pharmacokinetics |
Oxonol VI is stable at -20degC as a powder and in DMSO solution (100 mg/mL, 316.11 mM) for up to 6 months at -80degC. Ex/Em maxima: 523/630 nm. Storage should protect from light to prevent photobleaching.
|
| Toxicity/Toxicokinetics |
Standard laboratory safety precautions should be followed. Avoid dust formation, inhalation, and contact with skin and eyes. Use personal protective equipment and work in a fume hood when handling the dye powder.
|
| References | |
| Additional Infomation |
This compound is a research-use-only fluorescent probe, not an approved drug. It has faster response than Oxonol V. Molecular formula: C17H20N2O4; molecular weight: 316.35. Also known as Bis-(3-propyl-5-oxoisoxazol-4-yl)pentamethine oxonol.
|
| Molecular Formula |
C17H20N2O4
|
|---|---|
| Molecular Weight |
316.3517
|
| Exact Mass |
316.142
|
| CAS # |
64724-75-0
|
| PubChem CID |
121902
|
| Appearance |
Brown to black solid powder
|
| Density |
1.19g/cm3
|
| Boiling Point |
381.4ºC at 760 mmHg
|
| Flash Point |
184.5ºC
|
| Index of Refraction |
1.563
|
| LogP |
2.977
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
23
|
| Complexity |
639
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
SBJHIADVIBJMQL-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C17H20N2O4/c1-3-8-14-12(16(20)22-18-14)10-6-5-7-11-13-15(9-4-2)19-23-17(13)21/h5-7,10-11,18H,3-4,8-9H2,1-2H3
|
| Chemical Name |
4-[5-(5-oxo-3-propyl-2H-1,2-oxazol-4-yl)penta-2,4-dienylidene]-3-propyl-1,2-oxazol-5-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~316.11 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1611 mL | 15.8053 mL | 31.6106 mL | |
| 5 mM | 0.6322 mL | 3.1611 mL | 6.3221 mL | |
| 10 mM | 0.3161 mL | 1.5805 mL | 3.1611 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
